Biomanufacturing Industry News
-
Sumagen Initiates Clinical Testing Of Omnia Biologics Manufactured HIV Vaccine
1/12/2012
Biologics drug development and manufacturing services provider Omnia Biologics, Inc. (Omnia) (Rockville, MD) today announced that its customer Sumagen, Co., Ltd., (Seoul, S. Korea and London, ON) will begin clinical trials of their revolutionary HIV vaccine design.
-
Marken Announces Appointment Of Christopher O'Connell As New Chief Financial Officer
8/10/2011
Marken Ltd., a leading life sciences supply chain management organization, today announced the appointment of Christopher O'Connell as their new Chief Financial Officer (CFO) effective August 1, 2011.
-
Single-Use Bioreactors For Pharma: World Market 2011-2021
7/19/2011
How will the market for single-use bioreactors develop this decade? Our new report shows you that emerging market's revenue potential from 2011 to 2021, discussing its prospects.
-
Novavax's VLP Influenza Vaccine Named One Of Top 100 Drugs In Development Today
4/5/2011
Novavax, Inc. (NASDAQ: NVAX) announced that its virus-like particle (VLP) influenza vaccine has been named by the editors of R&D Directions magazine as one of the top "100 great investigational drugs in development" today.
-
CMC Biologics Completes First Stage Of Expansion With Addition Of Single-Use Facility
8/26/2010
CMC Biologics, a Contract Manufacturing Organization with manufacturing sites in Europe and the USA, today announced the completion of a new state-of-the-art disposable manufacturing facility at its Seattle, WA site.
-
Lilly Halts Development Of Semagacestat For Alzheimer's Disease Based On Preliminary Results Of Phase III Clinical Trials
8/17/2010
Eli Lilly and Company (NYSE: LLY) will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long-term Phase III studies showed it did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living.
-
Clearstone Central Laboratories And LabCorp Establish Global Strategic Collaboration For Clinical Trials
8/16/2010
Clearstone Central Laboratories, a leading provider of central laboratory services for late-stage clinical trials, announced today a global collaboration with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) through its Esoterix Clinical Trials Services division, providing clients with seamless access to CAP-accredited laboratories across both organizations in Belgium, Canada, China, France, Singapore and the United States.
-
CaldolorĀ® (Ibuprofen) Injection Shown to Significantly Reduce Fever In Malaria Patients In Newly Published Clinical Trial
7/13/2010
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that data supporting the efficacy of Caldolor in treating fever associated with falciparum malaria was published in the July edition of the peer-reviewed American Journal of Tropical Medicine and Hygiene.
-
Martek Biosciences Announces Restructuring Plans For Winchester, KY, Manufacturing Site
7/1/2010
Martek Biosciences Corporation (Nasdaq: MATK) announced today that it plans to restructure its Winchester, Ky., manufacturing facilities in an effort to streamline operations, improve capacity utilization, and reduce manufacturing costs and operating expenses.
-
It's Not Just the Sun: deCODE Discovers Sequence Variants Affecting Susceptibility To Skin Cancer
7/6/2009
Scientists at deCODE genetics (Nasdaq: DCGN) and academic colleagues from Europe and the United States today present in the journal Nature Genetics the discovery of common genetic risk factors for basal cell carcinoma (BCC) that affect people with fair and dark complexions alike.
This website uses cookies to ensure you get the best experience on our website. Learn more